StemEdit hiPSC B2M KO
RCRP053
Brand: StemEdit
Human iPSCs with a knockout of both copies of the B2M gene.
| Product name | Catalog number | Pack size | Price | Price | Price (USD) | Price (GBP) | Price (EUR) |
|---|---|---|---|---|---|---|---|
| StemEdit hiPSC B2M KO | RCRP053 | 1 × 10⁶ cells | Ask us | $ Ask us | £ Ask us | € Ask us |
Note: prices shown do not include shipping and handling charges.
Product Information
Ready-to-use Research-Grade HLA Class I knockout iPSCs made using REPROCELL’s RNA Reprogramming Technology.
These cells feature all the advantages of our RNA reprogramming technology, including no retention of reprogramming factors and easy culture in NutriStem hPSC XF Medium. They have been engineered using OpenCRISPR-1 to contain a B2M (HLA Class I) knockout mutation, which is carefully characterized and offers significant time savings compared to creating your own reprogrammed and edited cell lines.
Explore our other StemEdit Research iPSCs.
The parent line, StemRNA Clinical iPSC Clone LLF-34-F3, is also available for clinical and research use. Please contact us for more info: info-us@reprocell.com.
Table: Characteristics of StemEdit hiPSC B2M KO RPC-LLF-34-F3 Cells
| Cat. No.: | RCRP053 |
| Parent Strain ID | StemRNA Clinical iPSC Clone LLF-34-F3 |
| Donor Race: | Caucasian |
| Donor Sex: | Female |
| Donor Age: | 22 |
| Reprogramming Technology: | StemRNA Reprogramming Technology |
| Tissue Source: | Skin (Fibroblasts) |
| Karyotype: | Normal (46 XX) |
| Microbiology: | Negative for bacteria, virus, mycoplasma |
Figure: Immunofluorescence staining (Figure) and flow cytometry analysis (Table) for Pluripotency Markers
|
Marker |
Flow Positive Cells |
|
OCT4 |
95.7% |
|
Nanog |
97.3% |
|
SSEA4 |
96.6% |
|
SSEA1 (neg control) |
0.0% |
Figure: Expression of B2M in Knockout iPSCs and Wild Type iPSCs by flow cytometry. 
B2M protein is completely knocked out in B2M KO iPSCs.
The Role of B2M
In humans, the B2M protein is required for the presentation of HLA proteins A-G on the cell surface. Disruption of the B2M gene reduces T-cell activation and interferes with the T-cell-mediated immune response through inhibition of Class I HLA signaling.
Explore our other StemEdit Research iPSCs.
Stemgent and the StemEdit brand name are trademarks of REPROCELL Inc., Japan.